Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
4(22%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
6%
Ph phase_1
4
22%
Ph phase_3
3
17%
Ph phase_2
8
44%

Phase Distribution

4

Early Stage

8

Mid Stage

4

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
4(25.0%)
Phase 2Efficacy & side effects
8(50.0%)
Phase 3Large-scale testing
3(18.8%)
Phase 4Post-market surveillance
1(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

18

all time

Status Distribution
Active(6)
Completed(5)
Other(7)

Detailed Status

unknown7
Completed5
Recruiting3
Not yet recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (25.0%)
Phase 28 (50.0%)
Phase 33 (18.8%)
Phase 41 (6.3%)

Trials by Status

not_yet_recruiting211%
active_not_recruiting16%
completed528%
recruiting317%
unknown739%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT02896582Phase 2

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

Completed
NCT03215719Phase 2

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

Recruiting
NCT07046221Phase 2

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Not Yet Recruiting
NCT06943820Phase 1

AK129 Combination Therapy for Advanced Solid Tumors

Recruiting
NCT06879691Phase 4

A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma

Active Not Recruiting
NCT01504815Phase 3

Adaptive Radiation Treatment for Head and Neck Cancer

Completed
NCT05504278Phase 1

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Recruiting
NCT02760667Phase 2

Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer

Unknown
NCT05879796

Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer

Not Yet Recruiting
NCT03121716Phase 1

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

Completed
NCT01683175Phase 2

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

Unknown
NCT02766348Phase 2

Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

Unknown
NCT02001168Phase 3

Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Unknown
NCT01742767Phase 2

Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC

Unknown
NCT00209222Phase 3

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Unknown
NCT00083538Phase 2

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

Completed
NCT00301301

A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Completed
NCT00379717Phase 1

Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Unknown

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18